

➤ The Target

VEGF-R2 is almost exclusively expressed on endothelial cells. It transduces the action of the well characterized pro-angiogenic vascular endothelial growth factor (VEGF-A). In pathological situations that involve neovascularization as well as enhanced vascular permeability the VEGF/VEGF-R2 signaling is responsible for activated endothelium at the tumor site. Today, VEGF-R2 is a validated target for cancer therapeutics addressing solid tumors with induced blood vessel formation.

➤ Cellular Phosphorylation Assay

Immortalized human umbilical vein endothelial cells (HUE) are known to overexpress human VEGF-R2. Stimulation of these cells with its physiological ligand VEGF-A, results in a robust receptor autophosphorylation. Compounds are preincubated before cell stimulation to allow thorough target binding. Stimulation conditions are optimized to determine dose-related inhibition of the phospho-VEGF-R2 signal, which is subsequently quantified by Sandwich-ELISA technique. The assay is validated based on known inhibitors of VEGF-R2 kinase activity (see Fig. 1).





Figure 1: Assay validation.

Whereas Sunitinib blocks VEGF-R2 as a broad kinase inhibitor, PTK-787^[1] is known to inhibit the VEGF-induced phospho-VEGF-R2 signal in a highly specific manner. Both compounds were included in the validation process and the cellular VEGF-R2 assay generated highly reproducible IC_{50} values. The graphs show representative results.

[1] Wood, JM et al. (2000) Cancer Res. 60(8):2178-89.

➤ You ship your compounds – ProQinase performs the testing



- IC_{50} values are determined by testing 8 compound concentrations in semi-logarithmic steps (each concentration in duplicates).
- Quality assurance is provided by calculation of Z' factors for Low/High controls on each assay plate and by including a full IC_{50} curve for a reference inhibitor to monitor adequate dose/response relation in your assay run.

ProQinase disclaims any warranty explicitly or implied that the use of this service is free from third party intellectual property claims unless this is explicitly stated.